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Abstract 
Objectives  
The objectives of this study are to review fibrocystic changes of the breast, their causal and 
associated factors and their correlation to mastalgia, and then to review the available 
treatment options for mastalgia (caused by fibrocystic changes) short of surgery.   
Methods 
The author reviews all the articles obtained from a PubMed research on mastalgia and 
fibrocystic changes of the breast, published in English over the last 14 years. 
Results 
Fibrocystic changes of the breast are common and can be considered as a normal phase of 
breast development. These changes are sometimes asymptomatic; however, when painful, 
patients would seek medical advice. Lifestyle changes and the avoidance of certain dietary 
elements as well as the use of some non-pharmacological agents have shown some 
beneficiary effects. In severe cases, stronger pharmacological and hormonal agents are 
resorted to being more effective but are associated with greater side effects.  
Conclusion 
Fibrocystic changes of the breast are common and should not be considered a disease. When 
painful, reassurance and non-pharmacological measures should be used first as a treatment. 
Stronger pharmacological and hormonal agents hold more serious side effects. Some of these 
remedies are supported by good clinical evidence, while others are not. The ideal treatment 
for mastalgia caused by fibrocystic changes is to be identified by sound recent randomized 
controlled clinical studies on simple remedies before being performed on stronger ones. 
Treatment should start with simple lifestyle changes and advance with a stepwise fashion to 
stronger remedies only in those where other means fail.  
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Introduction 
  
ibrocystic breast changes as well as 
mastalgia are common conditions that 
women suffer from. They may occur 
separately or in combination. The nature of 
these changes as well as the associated 
factors responsible for their development 
are not fully understood by many who treat 
patients suffering from breast pain. 
Unfortunately, mastalgia caused by 
fibrocystic breast changes is treated by 
breast specialists as well as by those not 
specialized in breast diseases. This results in 
patients receiving inappropriately strong 
medication with severe side effects, where 
simpler remedies could have done the job 
more efficiently.  
 
Breast histology  
The life cycle of the breast consists of three 
main periods: development, mature 
reproductive life, and involution. The breast 
is identical in males and females until 
puberty. After the breast has developed, it 
undergoes regular changes in relation to the 
menstrual cycle that results in an increased 
rate of cell proliferation during the luteal 
phase leading to an increase in breast size1. 
Pregnancy results in a progressive increase 
in breast weight till term, and the breast 
involutes following pregnancy. Breast 
involution begins at some time after the age 
of 30 in nulliparous women. During 
involution the breast stroma is replaced by 
fat, so that the breast becomes less 
radiodense, softer, and ptotic (droopy). 
Changes in the glandular tissue include the 
development of areas of fibrosis, the 
formation of small cysts (microcysts), and an 
increase in the number of glandular 
elements (adenosis)1. This leads to a 
spectrum ranging from normal histologic 
features to features that mainly exhibit 
patterns of fibrous change and cyst 
formation, formerly called fibrocystic 
disease of the breast. Since this histologic 
pattern may be evident in up to 50 or even 
60 percent of women without breast disease, 
it led Love et al to suggest that fibrocystic 
“disease” does not exist2. The currently 
accepted term for this condition is 
‘fibrocystic change’, an emphasis that has 
been evolving in the literature3.  
 
Classification and Synonyms 
In the 10th revision of the International 
Statistical Classification of Diseases and 
Related Health Problems, (the ICD-10), 
fibrocystic disease or fibrocystic changes 
also known as chronic cystic mastitis and 
fibrocystic mastopathy is classified under 
‘benign mammary dysplasia’ category N60, 
and in case of ‘diffuse cystic mastopathy’ 
sub-category N60.1. If there is epithelial 
proliferation, it is classified under 
‘fibrosclerosis of the breast’ category N60.3. 
‘Mastodynia’ is classified under N64.44.    
 
Eponyms 
This entity (fibrocystic disease of the breast) 
has historically been termed as Bloodgood’s 
disease, Cooper's disease (after Sir Astley 
Paston Cooper), Phocas' disease, Reclus’ 
disease, Reclus’ syndrome (after Paul 
Reclus), Reclus-Schimmelbusch disease, 
Schimmelbusch disease and Tillaux-Phocas 
disease5. 
 
Are fibrocystic changes and Mastalgia 
synonymous? 
Fibrocystic changes of the breast involve 
various histological findings in both 
asymptomatic and symptomatic women, 
and are common in both groups. Fibrocystic 
changes and mastalgia are two different 
things although they commonly occur 
together. They can also occur separately, 
making the association between breast pain 
and fibrocystic histology inconsistent6. 
 
Mastalgia (Breast Pain) 
Mastalgia (breast pain) was described in the 
medical literature as early as 18297 and is a 
common complaint amongst women. Most 
of them describe premenstrual mild cyclic 
mastalgia (CM) that lasts for 1 to 4 days as 
“normal”8. Recent population based9, and 
breast clinic-based10,11 studies suggest that 
up to 70% of women under 55 experience 
breast pain. Although 45% of them report 
minimal to mild symptoms, about 25% 
report moderate-to-severe mastalgia lasting 
for more than 5 days. 
F 
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Etiology 
What causes fibrocystic breast condition to 
cause mastalgia? 
Researchers have found no clear hormonal 
or specific pathological processes that 
explain cyclical breast pain12. However, 
certain associations and factors cannot be 
ignored (Table 1). 
 
Table 1: Factors with possible relation to 
the development of Fibrocystic Changes of 
the breast. 
 
 
Age 
Breast pain is most common amongst 
women aged 30–50 years10. 
  
Hormones 
1. hormonal associations 
The fact that mastalgia in patients with 
fibrocystic changes is related to hormonal 
events, such as the menstrual cycle, 
pregnancy, menopause and hormone 
therapy suggests a relationship between the 
two.  
  
2. hormone therapy 
In one study 16% of women reported breast 
pain as a side effect of estrogen therapy and 
32% reported the same in cases of combined 
hormonal therapies13. Other researchers 
have also identified increased breast density 
during hormonal therapy14. On the other 
hand, hormonal contraceptive was found to 
be associated with significantly less 
mastalgia and premenstrual syndrome 
(PMS)9. 
 
3.  relationship to other premenstrual 
symptoms 
Most agree that CM and tenderness are part 
of the PMS12,15. Luteal-phase symptoms, 
including water retention, negative affect, 
impaired concentration and behavior 
change were significantly greater in women 
with severe CM compared to women 
without breast symptoms. Also, women 
with severe CM experienced more breast 
symptoms and negative affects in the 
follicular phase of the menstrual cycle16. A 
study of 30 subjects showed that most 
women whose symptoms met  the criteria 
for CM had experienced other premenstrual 
and somatic symptoms17. However, others 
have found that although premenstrual 
symptoms were common in women with 
CM, only 16% of women in one study18, and 
22.5 % in another study9 had sufficient 
symptoms that met the criteria for both CM 
and PMS. 
 
Duct ectasia 
Ultrasonographic measurement of the 
maximum mean width of the milk ducts 
was 1.8 mm in asymptomatic women, 2.34 
mm in women with CM, and 3.89 mm in 
women with non-CM (P<0.001). Ductal 
width correlated with pain intensity19.  
 
Other Risk Factors and High Risk 
Groups 
 
Stress appears to be a factor as women with 
severe breast pain seem to have had greater 
incidence of significant life events than 
women without severe breast pain9. Smoking 
as well as caffeine intake also seems to be risk 
factors9. 
  
Clinical Features 
 
Fibrocystic breasts are lumpy or nodular 
and although the breast changes categorized 
as "fibrocystic" are normal; they can cause 
breast pain and tenderness that is usually 
related to the period12. This glandular 
texture may be finely granular, nodular, or 
even grossly lumpy. Breast pain and 
palpable mass are the symptoms most 
frequently described by women presenting 
to general practitioners or breast clinics20, 21. 
Factors possibly related to Fibrocystic 
Breast Changes  
    1 Age 
2 Hormones 
    3 Premenstrual syndrome 
4 Duct ectasia 
5 Stress 
6 Smoking 
7 Caffeine 
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CM accounts for approximately 2/3 of 
breast pain in specialty clinics, whereas non-
CM accounts for the remaining 1/322. CM 
typically presents during the third or the 
fourth decade of life and the symptoms tend 
to persist with a relapsing course22. It 
usually starts during the luteal phase of the 
menstrual cycle and increases in intensity 
until the onset of menses, when it 
dissipates6. Mastalgia may be severe enough 
to influence usual daily activities11. In spite 
of that, mastalgia generally is 
underreported. Remission often occurs with 
hormonal events such as pregnancy or 
menopause. Only 14% of women with CM 
experience spontaneous resolution; 
however, 42% experience resolution at 
menopause22.  The outcome can be 
successful in most patients with 
reassurance, non-pharmacological measures 
and in some instances one of several 
effective medications23.  
 
Breast Pain Assessment 
 
Quantifying breast pain may be difficult 
because of its variability23,24. Before starting 
any therapy for breast pain, patients should 
be asked to document the frequency and 
severity of their pain on daily basis for at 
least one menstrual cycle using a visual 
analog scale. The pain scale is also helpful in 
assessing treatment response in mastalgia, 
which is characterized by the waxing and 
waning of symptoms and a high 
spontaneous remission rate24. In one study, 
the total breast pain score was found to be 
most efficiently estimated by a combination 
of a visual analog scale, present pain index, 
and quality-of life questions25. These 
measures are particularly important for CM 
as the diagnosis based on recall of 
symptoms is only 65% sensitive, and the 
diagnosis based on the prospective breast 
pain diary is 69%   specific17. Research 
criteria for the diagnosis of CM are (1) pain 
severity greater than 4.0 cm measured on a 
10.0-cm visual analog scale and (2) pain 
duration of at least 7 days per month11.  
 
 
Relationship to Breast Cancer 
 
Mastalgia is rarely considered as a 
presenting symptom of breast cancer6. In 
one study, the relative risk of Breast Cancer 
developing ranged between 0.3 and 0.7 in 
patients with breast pain and was 
significantly higher (1.9-3.0) only in patients 
aged > 40 years with breast lumps. They 
concluded that in symptomatic patients 
Breast Cancer risk is strictly related to age 
and independent of the referred 
symptoms26. Conversely, in a review of 1532 
women with breast pain (when women with 
breast pain as a sole complaint were 
excluded) the risk of breast cancer was 
lower in women having pain incidental to 
another presenting complaint27. In a recent 
case-control study of women referred for 
diagnostic breast imaging to evaluate pain, 
there were no differences between the 
mammographic findings and frequency of 
malignancy in women with pain compared 
with a matched control group undergoing 
routine screening28. However, because of the 
increased awareness of breast cancer, more 
women are seeking professional advice than 
ever before23, 29,30,31,32. Classically, breast pain 
associated with cancer is unilateral, constant 
and intense8.  
 
Treatments (Table 2) 
 
General 
A wide variety of therapies are used, but 
danazol is the most commonly used by 75% 
of surgeons. Breast specialists tend initially 
to use methods that are associated with 
fewer side-effects and reserve stronger 
treatments such as danazol and 
bromocriptine for more difficult cases. 
Hormonally active medications are more 
effective for patients with CM and are 
prescribed only for patients with severe 
prolonged symptoms33,34. 
 
Nonpharmacological Interventions 
Education and reassurance 
Education and reassurance are integral parts 
of the management of mastalgia and should 
be the first-line of treatment35.  
A review of mastalgia in patients with fibrocystic breast disease  
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Table 2: Treatment options for mastalgia of the breast. 
Remedy Evidence For Evidence  
Against 
Other Remarks 
Non-Pharmacological, Non- 
Nutritional Recommendations 
        Education and reassurance         35   
        Relaxation Training                     36   
        Wearing A Bra                              35,38   
Nutritional Recommendations 
        Dietary Fat Reduction                 39,40 41,42,43  
Dietary Fiber                    43  
Methylxanthine Restriction       31   
Nutritional Supplements and  
Herbal Agents 
        Vitamin E 46,47,48 35  
        Soy 54,55   
        Fish oil  56  
        Evening Primrose Oil 12,24,33,48, 57, 
58 
31,35,41,56,60 Not to be used in patients on 
anticonvulsant therapy. Its safety during 
pregnancy or lactation has not been 
established. 
        Flax Seed Oil 35 62  
        Chasteberry 44,63   
Pharmacological Interventions 
   Non-Hormonal Medications 
        Simple Analgesics 35,65,66,67 23  
Hormonally Active Medications 
        Oral Contraceptives 69,70,71 68,70,71  
         Progesterone, Progestogens + 
Progestins 
72   
        Antigonadotropins 
             Danazol 46,79,80  To reduce side effects reduce the dose 
once a response is achieved and/or 
luteal-phase administration. It is 
contraindicated in women with H/O 
thromboembolic disease and potentially 
teratogenic.  
        Dopamine Agonists 
             1-Bromocriptine 84 
 
86 Side effects less if the drug is taken with 
meals. Strokes, seizures and death have 
been reported after its use to inhibit 
lactation, and the US FDA has 
withdrawn its licence for this indication.  
             2-Lisuride 87   
             3-Quinagolide 88   
Selective Estrogen Receptor  
Modulators  (S.E.R.M.) 
             1-Tamoxifen 80,91,92 8,93 Tamoxifen has a risk of potentially 
serious adverse effects and is 
contraindicated in pregnancy because of 
potential teratogenicity.  
             2-Toremifene 94   
        Gonadotropin-Releasing 
Hormone Agonists: 
  Adverse effects related to the 
hypoestrogenic state produced by these 
medications are frequent and often 
severe 
             Buserelin  96 High decline in trabecular bone mineral 
density. 
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Psychological Associations and Relaxation 
Training 
The potential psychological origin of breast 
pain has been explored throughout the 
medical literature. As far back as 1829, Sir 
Astley Cooper wrote that women seeking 
advice for breast pain usually had “a 
nervous and irritable temperament.”7. More 
recently, anxiety and other psychological 
disorders have been found by others to be 
more frequent among women with 
mastalgia compared with asymptomatic 
women36. In another study, women with 
breast pain had, in addition, increased 
somatization, and history of emotional 
abuse compared with women with breast 
lumps alone37. This led some to explore the 
effect of relaxation on breast pain. H.Fox et 
al found that approximately 61% of women 
who listened to relaxation audiocassettes 
daily for 4 weeks experienced substantial or 
complete relief of breast pain compared to 
25% of controls (P< 0.05). The subjects also 
had substantially more pain-free days and 
less anxiety than controls36. 
 
Stop Smoking 
Patients with mastalgia should stop, or at 
least reduce the number of cigarettes taken 
daily, based on a study that identified 
smoking as being a factor associated with 
mastalgia9. 
 
Wearing A Bra 
B.R. Mason et al have hypothesized that 
breast pain is mainly associated with the 
movement of breast tissue, and have shown 
that wearing an external breast support 
reduced absolute vertical movement and 
maximum downward deceleration force on 
the breast. Breast support also reduced 
perceived pain. Of the three garments 
examined in this study, the fitted sports bra 
provided superior support resulting in pain 
reduction38. V. Rosolowich et al also agree 
that the use of a well-fitting bra that 
provides good support should be 
considered for the relief of mastalgia35.  
 
Nutritional Recommendations 
 
Dietary Change 
The effectiveness of dietary interventions to 
reduce breast pain are continually 
undergoing investigations. The following 
have recently been studied. 
 
 Dietary Fat 
Lower dietary fat intake has been associated 
with less severe mastalgia symptoms39. By 
reducing dietary fat, other parameters that 
may be related to mastalgia are altered, 
including mammographic breast density40. 
However some claim that the effect of 
decreased dietary fat intake on other 
fibrocystic changes of the breast is limited 
and also claim that in order to derive benefit 
from this approach, women must decrease 
fat intake to less than 20% of total daily 
caloric intake41. This reduction in fat intake, 
in addition to being difficult to sustain, may 
not be optimal in some cases42. 
 
Fruits,Vegetables,andDietaryFiber 
The results of T.E. Rohan et al suggest that a 
modest reduction in fat intake and an 
increase in fruit, vegetable, and grain intake 
does not alter the risk of benign proliferative 
breast disease43. 
 
Methylxanthine (Caffeine) Restriction 
Caffeine reduction or elimination is 
recommended by many specialists to 
alleviate breast pain, and although many 
women reported that it alleviates their 
breast pain, clinical studies have not shown 
consistent findings6. Since caffeine is present 
in coffee, tea, chocolate and cola, this makes 
it difficult to completely eliminate from the 
diet; even in clinical trials. It also puts a big 
question mark on studies performed using 
total elimination of methylxanthines from 
the diet for long periods. In addition, some 
recommend that women with breast pain 
should not be advised to reduce caffeine 
intake35. An association between 
methylxanthines (caffeine or theophylline) 
and breast symptoms of pain, tenderness, 
nodularity, has been reported by other 
investigators9. In an uncontrolled study, 
61% of women with breast pain who 
substantially decreased caffeine intake for 1 
year had decreased pain or complete relief31. 
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Many of us will continue to advise patients 
to practice some restriction in their caffeine 
intake on the basis of clinical experience and 
the few studies with breast pain as a discrete 
outcome, especially in women with 
problematic breast pain who have moderate 
to heavy caffeine consumption9. 
 
Nutritional Supplements and 
Herbal Agents 
 
Interest is growing in herbal agents, 
nutritional supplements and alternative 
strategies for treatment of breast pain6. 
Patients frequently use herbs and dietary 
supplements to treat chronic conditions that 
are poorly responsive to prescription drugs, 
or when prescription drugs carry a high side 
effect burden44. Physicians must be 
cognizant that herbal agents and nutritional 
supplements are not standardized or 
monitored for adulteration45. Potential 
interaction with medications and other 
herbal medicinal also must be considered. 
 
Vitamins 
Vitamin E (ǂ-tocopherol) 
 Vitamin E is by far the most commonly 
used and most commonly studied vitamin 
to use as a treatment for breast pain. While 
some go as far as stating that vitamin E 
should not be used for the treatment of 
mastalgia35, when comparing vitamin E to 
danazol, Khanna et al found that the 
treatment with vitamin E showed a 41% 
response rate with minimal side-effects, 
while treatment with danazol showed a 
72.1% response rate but was associated with 
side-effects in one third of the patients46. 
More recently, a study concluded that a 2-
month prescription of vitamin E has positive 
therapeutic effects on cyclic mastalgia. 
Given its lack of significant side effects, 
vitamin E can be considered a safe 
alternative to hormonal therapies currently 
used in the treatment of cyclic mastalgia47. 
Also, Pruthi et al concluded that daily doses 
of 1,200 IU vitamin E, 3,000 mg Evening 
Primrose Oil (EPO), or vitamin E and EPO 
in combination at these same dosages taken 
for six months may decrease the severity of 
CM mastalgia48. 
 
Soy 
Soy is a rich source of the isoflavones 
genistein and daidzen, which exert their 
effect by binding to estrogen receptors49. In 
premenopausal women, this increases the 
duration of the follicular phase of the 
menstrual cycle and delays menstruation. In 
addition, it may decrease midcycle surges of 
luteinizing and follicle-stimulating 
hormones43 and decrease estradiol levels50. 
Others have found that flavonoids exhibit 
significant steroid hormone activity51. Some 
studies of soy on breast epithelium revealed 
markers of increased proliferation52, 
whereas others did not53. R.M. Fleming 
conducted a study to examine the effect of 
daily soy protein consumption which 
showed both objective and subjective 
reduction in both breast tenderness and 
fibrocystic disease54. In another study, the 
reduction of pain was significantly better 
than placebo55.  
 
Fishoil 
J. Blommers et al studied the effect of both 
EPO and fish oil on breast pain and 
concluded that neither EPO nor fish oil 
offered clear benefit over control oils in the 
treatment of mastalgia56. 
 
Evening Primrose Oil (EPO) 
There is some evidence suggesting that 
women with mastalgia have increased levels 
of saturated fatty acids and reduced 
proportions of essential fatty acids, 
especially of gamma-linolenic acid (GLA). 
These abnormal fatty acid profiles may 
cause hypersensitivity of the breast 
epithelium to circulating hormones. GLA is 
believed to restore the 
saturated/unsaturated fatty acid balance 
and decrease sensitivity to steroidal 
hormones41. Also, low levels of the GLA 
metabolite, dihomogamma-linolenic acid 
may affect breast sensitivity to prolactin via 
prostaglandins41.  EPO is rich in Omega-6 
Fatty Acids. GLA is an omega-6 fatty acid 
found primarily in vegetable oils including 
EPO. EPO typically contains 9% GLA by 
Khalid Rida Murshid 
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weight57.  For women with CM who elect 
treatment, EPO has been advocated by 
many as an initial option12,24,33,58, and several 
have reported efficacy in the treatment of 
breast pain with low adverse effect rates48,57. 
One randomized controlled trial found that 
most adverse effects were gastrointestinal. 
However, there were no significant 
differences in rates between the EPO plus 
multivitamins and the placebo plus 
multivitamins group59. Proponents of its 
usefulness suggest the dosage for breast 
pain to be 3000 mg/d (in divided doses), 
and claim that patients may continue to 
improve after 3 months of treatment and 
therefore recommend assessing response to 
therapy after at least 6 months57.  GLA 
however, may affect the seizure threshold; 
for this reason, some researchers advise 
against its use in patients requiring 
anticonvulsant therapy45.  In addition, the 
safety of EPO during pregnancy or lactation 
has not been established. Its benefits have 
been found in some studies to be only 
modestly better than placebo, and some 
question its therapeutic value for breast 
pain31,35,41,56,60.  
 
Borage Seed Oil 
Although borage is the highest known 
plant-based source of gamma-linolenic acid 
(GLA), the seed oil content being between 
26-38% and the oil is often marketed as 
"starflower oil" or "borage oil" for uses as a 
GLA supplement61, I have not come across 
any recent studies on its use in mastalgia. 
 
Flax Seed Oil 
Although V. Rosolowich et al claimed that 
flaxseed should be considered as a first-line 
treatment for CM35, E. Basch et al performed 
an extensive electronic search in an attempt 
to evaluate the scientific evidence on 
flaxseed. They found that most of the 
available evidence investigates the efficacy 
of alpha-linoleic acid found in flaxseed 
compared with fish oil, and state that almost 
all of the available studies are poor quality 
that do not support recommendations for 
any condition at this time62. 
 
Chasteberry (Vitex agnus-castus) 
Theoretical mechanisms of the actions of 
Vitex agnus-castus are that it binds to 
opioid, histamine, and estrogen receptors63, 
or acts via dopaminergic and prolactin-
suppressant effects64. In a study of the fruit 
extract of Vitex agnus-castus (chaste tree 
berry) in 1634 subjects for 3 menstrual 
cycles, 93% of the subjects reported 
improvement in symptoms related to 
premenstrual syndrome and 81% of subjects 
rated their status after treatment as much 
better or very much better. Few adverse 
effects were identified63. 
 
Pharmacological Interventions 
 
Simple Analgesics 
It is very likely that patients would have 
already used simple mild over the counter 
analgesics before seeing their doctor to 
prescribe. In one study, topical application 
of the nonsteroidal anti-inflammatory 
agents diclofenac and piroxicam yielded 
satisfactory relief in 81% of 26 women with 
severe cyclic, noncyclic, and surgical scar–
related breast pain65. In another study, 
Rosolowich et al recommend that topical 
non-steroidal anti-inflammatory gel, such as 
diclofenac 2% in pluronic lethicin organogel, 
be considered for pain control for localized 
treatment of mastalgia35. S. Qureshi and N. 
Sultan found topical non-steroidal anti-
inflamatory drugs (NSAIDs) to be a safe, 
effective, rapid and acceptable mode of 
treatment for CM and non-CM in addition 
to being superior to EPO in all aspects66. A 
prospective, randomized, blinded, placebo-
controlled study of topical diclofenac 
showed significant pain reduction in 
patients with CM as well as those with non- 
CM compared with placebo. No adverse 
effects occurred67. Conversely, another 
study of topical ibuprofen used in clinical 
practice determined no beneficial effect on 
breast pain23. 
 
Hormonally Active Medications 
Most researchers favor less aggressive 
measures before hormonal agents are 
embarked upon. However when these 
measures fail, danazol, bromocriptine, or 
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tamoxifen are the most widely resorted to, 
while focusing on a balance between relief 
of pain and side effects of these hormonal 
agents. Many oral contraceptives list breast 
pain and tenderness as potential adverse 
effects. Eliminating or decreasing the dose of 
estrogen in an oral contraceptive or 
hormone regimen is often effective in 
clinical practice, particularly if the onset of 
symptoms is temporally related to the 
initiation or change of medication6.  
 
Oral Contraceptives (OCs ), Estrogen, and 
Progesterone 
While some studies of low-dose OCs (20 Ǎg 
ethinyl estradiol) have found no increased 
breast symptoms compared with placebo68. 
Others have shown that many women 
reported a reduction in severity and 
duration of cyclic breast discomfort and 
PMS while taking OCs9. A multicenter case-
control study was performed on  women 
receiving medroxyprogesterone acetate 
(Depo-Provera) for contraception compared 
with age matched controls. Frequent breast 
pain and medication use for breast pain 
were noted in 9% and 5%, respectively, of 
women using Depo-Provera compared with 
21% and 9% of women in the control 
group69. TE Rohan and AB Miller 
investigated the association between OC use 
and the risk of benign breast disease (BBD), 
overall and by histological subtypes, within 
the 56,537 women in the Canadian National 
Breast Screening Study (NBSS). There was 
an inverse association between the use of 
OCs and the risk of all types of BBD 
combined. The risk of BPED with atypia was 
increased somewhat in association with OC 
use for the use of more than 7 years, but not 
in a dose-dependent manner70. In a follow 
up study on the 17,032 women in the 
Oxford-Family Planning Association study 
using different methods of contraception, M 
Vessey and D Yeates found that low-dose 
combined OCs containing <50 mcg estrogen 
appear to reduce the risk of hospitalization 
for fibroadenoma and chronic cystic disease  
as well as older preparations containing 
higher doses of estrogen. The apparent 
protective effect was not present for women 
using progestogen-only OCs71. 
 
Hormonal Supplements 
 
Progesterone, Progestogens and Progestins 
A progestin is a synthetic progestogen that 
has progestinic effects similar to 
progesterone. The two most common uses 
of progestins are for hormonal contraception 
(either alone or with an estrogen) and to 
prevent endometrial hyperplasia from 
unopposed estrogen in hormone 
replacement therapy61. In a controlled, 
randomized, double-blind, parallel-group 
study by UH Winkler et al, 31 women with 
mastopathy/mastodynia were treated with 
the progestins medrogestone or 
dydrogesterone (10 mg/day) from day 14 to 
day 25 for six cycles. They concluded that 
cyclic administration of these low-dose 
progestins proved to be an effective and safe 
treatment of mastodynia and mastopathy, 
evidenced by improvement in objective 
parameters in more than 50% of patients. 
Improvement was particularly marked in 
women with low progesterone levels in the 
second half of the cycle. After six treatment 
cycles, 75% of the patients treated with 
dydrogesterone and 86% of the patients 
treated with medrogestone were completely 
pain-free72. 
 
Hormone Replacement Therapy (HRT) 
Although HRT is not( in itself) a treatment 
for mastalgia or fibrocystic changes of the 
breast, it is mentioned here due to its strong 
causative relationship with breast changes. 
In an attempt to study the association 
between HRT use and the risk of benign 
proliferative epithelial disorders of the 
breast (BPED), TE Rohan and AB Miller  
found that in post-menopausal women, in 
whom most of the reported use occurred, 
there was a positive association between 
duration of HRT use and the risk of BPED73. 
LA Mattsson and T Sporrong reported a 
lower incidence of mastalgia during 
treatment with low dose regimen HRT 
compared to high doses. They suggested for 
cases requesting HRT to begin with low 
dose formulations since these doses are 
sufficient for the majority of women74. MC 
Yenen et al found that tibolone (a synthetic 
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steroid hormone acting as an agonist at all 
five of the Type I steroid hormone 
receptors61), was associated with a decrease 
in cyst dimensions which was statistically 
significant in benign cystic mastopathy 
patients compared to other hormone 
replacement therapy regimens75. A. 
Ozdemir et al when studying 
mammographic and ultrasonographic 
changes in the breast related to HRT showed 
that mammographic density changes related 
to HRT are dependent on the selected 
hormone regimen. The degree of density 
increase was evidently minimal in tibolone 
users compared to others.  Formations of 
breast cysts or solid lesions did not seem to 
be related to HRT76. In a study by 
E.Lundström et al, HRT regimens were 
shown to have different effects on the 
normal breast. An increase in 
mammographic density was noted much 
more commonly among women taking 
continuous combined HRT (40%) compared 
to those using oral low-dose estrogen (6%) 
and transdermal (2%) treatment. They found 
the increase in density to be apparent as 
early as the first visit after starting HRT. 
During long-term follow-up, there was very 
little change in mammographic status77. 
M.D.Cahn et al stated that the use of HRT 
may promote lesions that predispose to 
cancer, and recommended that patients 
treated with HRT undergo vigilant 
surveillance by way of examination and 
mammography78. A change in dose, 
formulation, or scheduling should be 
considered for women on HRT, and HRT 
may be discontinued if appropriate35. Also, 
contraception is important during treatment 
and should be discussed with patients6. 
 
Powerful Drugs With Hormonal Effects 
Antigonadotropins; Danazol 
Danazol is a derivative of the synthetic 
steroid ethisterone, a modified testosterone. 
It was approved by the U.S. Food and Drug 
Administration (FDA) as the first drug to 
specifically treat endometriosis in the early 
1970s61. It suppresses gonadotropin 
secretion, prevents luteinizing hormone 
surge, and inhibits ovarian steroid 
formation and is approved by the FDA for 
treatment of mastalgia6.  While employing 
danazol in the management of cases with 
endometriosis, an unexpected voluntary 
comment patients frequently offered was 
that breast pain, nodularity and 
premenstrual engorgement were alleviated. 
This finding led some workers to the 
treatment of women with mammary 
dysplasia with danazol. Danazol 
subsequently was found, in controlled 
clinical trials, to considerably relieve breast 
pain and tenderness in the women treated79. 
In addition, comparative studies were 
conducted. In one such study, treatment 
with vitamin E showed 41% response rate 
with minimal side-effects while treatment 
with danazol showed 72.1% response rate 
but was associated with side-effects in one 
third of the patients46. Unfortunately, 
adverse effects occur with the use of 
danazol. They are dose related and 
primarily androgenic, including menstrual 
irregularity or amenorrhea, acne, hair loss, 
decrease in voice pitch, weight gain, 
headache, nausea, rash, anxiety and 
depression.  Attempts at reducing side 
effects included reducing the dose once a 
response is achieved and/or luteal-phase 
administration of danazol (confining 
treatment to the 2 weeks preceding 
menstruation). These were shown to relieve 
premenstrual breast pain in women with 
PMS without increased adverse effects 
compared with placebo80. However, danazol 
is contraindicated in women with a history 
of thromboembolic disease, is potentially 
teratogenic and can interfere with oral 
contraception so that women who could 
become pregnant should use mechanical 
contraception33,58,81. 
 
Anti-Progestins 
Gestrinone 
Gestrinone is a synthetic steroid, reported to 
have androgenic, antioestrogenic, and 
antiprogestogenic properties in a way 
similar to danazol82. Gestrinone reduces 
ovarian hormone secretion, decreases 
follicular development and suppresses the 
midcycle surge of follicle-stimulating 
hormone and luteinizing hormone83. 
Adverse effects are primarily androgenic, 
A review of mastalgia in patients with fibrocystic breast disease  
 
11 
J T U Med Sc 2011; 6(1) 
the most common complaints being acne, 
seborrhea and weight gain. However, I have 
not come across any recent study of value 
on its use in the treatment of mastalgia.  
 
Dopamine Agonists 
The rationale behind the use of dopamine 
agonists to treat breast pain is the increase in 
thyrotropin-induced prolactin secretion 
detected in women with mastalgia. 
 
1. Bromocriptine 
Bromocriptine is a dopamine agonist which 
was found to significantly decrease breast 
pain, heaviness, and tenderness84. Clinical 
improvement generally occurs in 47% to 
88% of symptomatic women and is often 
sustained after cessation of the medication6. 
Some researchers advocate using the 
prolactin response to thyrotropin-releasing 
hormone (see below) to predict response for 
bromocriptine84. This was proved useful in a 
study using 2.5 mg b.i.d. of bromocriptine 
for 3-6 months, 73.6% of the subjects with an 
abnormal response experienced effective 
mastalgia treatment compared with 23.5% of 
subjects with a normal response, the 
difference was statistically significant84. 
Bromocriptine side effects seem to be less if 
the drug is taken with meals85. However, 
other side effects are much more serious. 
Strokes, seizures and death have been 
reported after the use of bromocriptine to 
inhibit lactation, and the US FDA has 
withdrawn its licence for this indication86.  
 
2. Lisuride 
Lisuride is an antiparkinson agent of the iso-
ergoline class, chemically related to the 
dopaminergic ergoline Parkinson's drugs 
and is used to lower prolactin61. In a double-
blind randomized prospective study on 60 
premenopausal women with premenstrual 
mastalgia, where the study and control 
groups consisted of 30 women each. The 
patients were given one tablet daily (0.2 mg) 
of lisuride maleate or placebo orally for 2 
months. Severity of mastalgia was evaluated 
using the visual analog scale. Mastalgia 
subsided significantly in women receiving 
lisuride maleate compared with controls, 
and there were no significant side effects. 
Prolactin levels decreased significantly in 
the group receiving lisuride, which 
correlated well with pain resolution87. 
 
3. Quinagolide 
Quinagolide is a selective, Dopamine 
receptor D2 agonist that is used for the 
treatment of elevated levels of prolactin61. In 
a pilot clinical trial on 52 patients, 75 microg 
Quinagolide given once per day was 
administered for the treatment of CM. 
Linear analogue charts were used for the 
assessment of response. Decrease in breast 
pain, heaviness, tenderness and serum 
prolactin level on the one hand, and 
increases in the serum estradiol and 
progesterone levels on the other hand were 
noted after 3 and 6 months administration 
and were statistically significant. The 
beneficial effect of Quinagolide also lasted 
after the cessation of treatment. Adverse 
effects like nausea, low blood pressure, 
dizziness and constipation were rarely 
reported88. 
 
Selective Estrogen Receptor 
Modulators (S.E.R.M.) 
 
1. Tamoxifen 
Tamoxifen is an antagonist of the estrogen 
receptor in breast tissue via its active 
metabolite, hydroxytamoxifen and behaves 
as an agonist In other tissues such as the 
endometrium.. Hence tamoxifen may be 
characterized as a mixed 
agonist/antagonist61; and the use of it in 
large numbers of premenopausal women in 
breast cancer prevention trials has increased 
familiarity with this medication in younger 
women without breast cancer89,90. 
Tamoxifen 10 mg daily or danazol 200 mg 
daily should be considered when first-line 
treatments of mastalgia are ineffective35. 
Tamoxifen was found to be effective in 
reducing pain in women with CM and also, 
but to a lesser degree, in women with non-
CM80,91. R. Grio et al, in a randamised 
controlled study on 88 women, aged 22–44 
years, found that 8 months of tamoxifen 
increased the proportion of women who 
achieved complete recovery compared with 
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placebo (90% with tamoxifen verses 0% with 
placebo)92. Tamoxifen has a risk of 
potentially serious adverse effects, with the 
principal concerns being deep venous 
thrombosis and endometrial cancer. Also, 
hot flashes, nausea, menstrual irregularity, 
vaginal dryness or discharge, and weight 
gain have been associated with tamoxifen  
treatment6.  
Adverse effects occurred more frequently 
with tamoxifen 20 mg than with tamoxifen 
10 mg between days 15 and 25 of the 
menstrual cycle91. And when comparing 
tamoxifen dosages and duration for breast 
pain, the 10 mg/d dosage of tamoxifen was 
as effective as the 20 mg/d dosage with 
fewer adverse effects91. One outpatient 
based randomized controlled trial (RCT) on 
93 women with severe CM compared three 
treatments over 6 months: danazol 200 mg 
daily, tamoxifen 10 mg daily, and placebo. 
The RCT found that tamoxifen was more 
effective than danazol, both at the end of 
treatment and 12 months after treatment. 
However, 4 women taking tamoxifen 
withdrew from the study owing to adverse 
effects of treatment, compared with 3 of 
those taking danazol. Reported adverse 
effects included an increase in weight (31% 
with danazol v 0% with tamoxifen), 
deepening of the voice (13% with danazol v 
0% with tamoxifen), menorrhagia (13% with 
danazol v 6% with tamoxifen), and muscle 
cramps (9% with danazol v 0% with 
tamoxifen), hot flushes (12% with danazol v 
25% with tamoxifen), and vaginal discharge 
(9% with danazol v 16% with tamoxifen; P 
values not reported)80. Nonetheless, 
tamoxifen, like the other hormonal 
interventions, should be reserved for 
women with severe mastalgia refractory to 
other measures6,8.  It should be administered 
under close supervision and for a limited 
period of time8. However, tamoxifen is 
contraindicated in pregnancy because of 
potential teratogenicity93.  
 
2. Toremifene 
Toremifene citrate is a S.E.R.M. which helps 
oppose the actions of estrogen in the body61. 
In a double-blind RCT, 104 patients with 
moderate to severe mastalgia received 
toremifene citrate, 30 mg daily, and 91 a 
placebo tablet for 3 menstrual cycles and 
were followed up for breast pain score and 
adverse events. All women recorded breast 
pain daily on a visual analogue scale chart. 
More women reported a reduction of 50% or 
more in pain scores with toremifene 
compared with placebo (69.2% v 31.9% p < 
0.001). Among the patients with CM, the 
response rate for toremifen was 76.7% v 
34.8% for placebo (p<.001). In contrast, the 
response rate of patients with non-CM was 
48.1% for toremifene and 24.0% for placebo 
(p= .09). The RCT found that women in the 
toremifene group reported adverse effects 
(menses disturbances, dizziness, vaginal 
discharge, and nausea), slightly but not 
significantly higher than the placebo group 
(50.5% v 42.9%  p = 0.45).  Showing that 
toremifene effectively relieves moderate and 
severe CM and tends to exert a positive 
therapeutic effect on non-CM, without 
increasing the incidence of intolerable 
adverse event94. 
 
Gonadotropin-Releasing Hormone Agonists 
A gonadotropin-releasing hormone agonist 
(GnRH agonist) is a synthetic peptide 
modeled after the hypothalamic 
neurohormone GnRH that interacts with the 
GnRH receptor to elicit the release of the 
pituitary hormones FSH and LH61. As a 
result, these agents reliably decrease 
estrogen levels in women. In addition, 
extremely low levels of progesterone, 
ovarian androgens, and prolactin result95. 
Although the use of GnRH agonists is 
promising, few data are currently available 
to support their clinical use for treatment of 
mastalgia. They have troublesome and 
potentially serious adverse effects that must 
be considered in future studies to define 
their therapeutic role for breast pain6. 
Adverse effects related to the 
hypoestrogenic state produced by these 
medications are frequent and often severe, 
including hot flashes, headaches, nausea, 
fatigue, depression, anxiety, irritability, 
vaginal dryness, and decreased libido. 
Decline in trabecular bone mineral density is 
as high as 6% within 6 months of treatment 
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with the GnRH agonist Buserelin. Although 
usually reversible, treatment duration is 
limited by this effect96.  
 
Other Considerations 
 
The Thyrotropin-Releasing Hormone (TRH) 
Prolactin (PRL) Response Test (TRH Test) 
Using serial measurements of prolactin 
plasma levels after an intravenous injection 
of TRH, (TRH test), patients were divided in 
two groups:  
1- Patients with abnormal PRL response to 
TRH  
2-  Patients with normal PRL response to 
TRH 
N. Rea et al found that bromocriptine 
treatment, 2.5 mg b.i.d. for 3-6 months, was 
effective in 73.6% of patients with abnormal 
TRH test and in 23.5% of patients with 
normal TRH test: the difference was 
statistically significant. On the other hand, 
76.9% of patients with either normal TRH 
test or those resistant to bromocriptine 
therapy had a favorable response to 
percutaneous progesterone and systemic 
NSAIDs. These results seem to confirm the 
hypothesis that PRL response to TRH could 
be used to identify patients affected with 
CM that are likely to benefit by 
bromocriptine treatment84.  
 
Sodium Iodide, Protein-Bound Iodide, And 
Molecular Iodine 
L. Patrick claims that although above the 
established safe upper limit of 1 mg, 3 to 
6mg doses of iodine are safe and studies 
using these relatively high doses of iodine to 
treat fibrocystic breast disease may reveal an 
important role for iodine in maintaining 
normal breast tissue architecture and 
function. He also suggests that iodine may 
also have important antioxidant functions in 
breast tissue and other tissues that 
concentrate iodine via the sodium iodide 
symporter97. 
 
Conclusion 
 
Fibrocystic changes of the breast commonly 
affect women in their third or forth decades 
and should not be considered a disease but 
rather a phase of breast development and 
involution. Fibrocystic changes are 
occasionally associated with breast pain. 
Mastalgia caused by fibrocystic changes has 
been treated by a vast array of remedies 
ranging from simple re-assurance and a 
change in lifestyle, to non-pharmacological 
and pharmacological agents, the latter may 
be associated with serious side effects. Some 
of these remedies are supported by good 
clinical evidence, while others continue to be 
used simply because the treating physician 
feels his/her patients respond to it. The 
ideal treatment for mastalgia caused by 
fibrocystic changes remains to be identified 
by sound recent randomized controlled 
clinical studies. These studies should be 
done on the simplest of remedies before 
being performed on the stronger remedies 
with considerable side-effects. Hopefully, 
the results revealed by these studies will 
open the path towards a systematic 
approach to the treatment of a common 
condition which many women suffer (or are 
deemed to suffer) from. Treatment should 
start with simple lifestyle changes and 
advance in a stepwise fashion to abstinence 
from certain substances to mild remedies 
and finally to stronger remedies only in 
those where other means fail. Only then can 
this condition be conquered with the least 
adverse effects. 
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